News | March 24, 2010

Moderate Hypofractionated Treatment with Chemotherapy Shows Low Side Effects

March 24, 2010 - A moderately aggressive hypofractionation schedule can be used along with chemotherapy, with low side effects, according to the first published results from a study on the concurrent use of hypofractionated TomoTherapy radiation treatments and chemotherapy for unresectable locally-advanced non-small cell lung cancer (NSCLC).

The Department of Radiation Oncology at the Universitaire Ziekenhuis (UZ) Brussel in Brussels, Belgium, conducted the trial, results of which were published in the journal Cancer (Volume 116, Issue 1, Pages 241-250, Jan 2010).

Previous studies have shown an increase in the rate of tumor control via either escalating biologically effective radiation dose or the addition of chemotherapy concurrent with the course of radiation. This trial tests the feasibility of dose escalation along with concurrent chemotherapy, taking advantage of the accuracy and dose conformity of helical TomoTherapy treatments in minimizing radiation damage to normal tissues.

The study focused on stage III non-small cell lung cancer. Various strategies have been tried to improve outcomes for later stage lung cancer, including increasing dose by increasing the number of fractions (with conventional fractionation of ~2 Gy/fx), increasing dose by increasing fraction size (hypofractionation of up to ~3 Gy/fx), and using chemotherapy at the same time as radiation ("concurrent" chemotherapy).

Increasing the number of fractions has been shown to be of limited benefit because of the lengthening of the overall treatment course and consequent tumor repopulation. Concurrent chemotherapy with conventional fractionation is the standard of care in the United States, after clinical trials showing improved survival over giving chemo either before or after the course of radiation, but it means that the patient will be more likely to incur side effects for a given radiation dose because of an additive effect. Hypofractionation even without concurrent chemo has been shown to be promising in terms of survival. But researchers found in this study that a moderately aggressive hypofractionation schedule can be used along with chemotherapy, with low side effects.

Tomotherapy said that a larger phase II study being started by UZB will add to the evidence that this mode of treatment is safe and effective.

For the complete study: http://www3.interscience.wiley.com/cgi-bin/fulltext/122684509/HTMLSTART?...

For more information: www.tomotherapy.com

Related Content

ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...
360_NW_Proton_Center_Gantry_Room_Back_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 photo view behind the gantry room at the ...
360_NW_Proton_Center_Inclined_Room_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 view of Treatment Room 3 (of 4) at the N...
NW Proton Center Gantry Room Front
360 Photos | 360 View Photos | February 27, 2019
This is a 360 photo view inside the gantry room at the...
Videos | Proton Therapy | February 26, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...